Off-Label Uses of Ocaliva (Obeticholic Acid)
Medically reviewed by Veronica Hackethal | MD, MSc, Harvard University | University of Oxford | Columbia Vagelos College of Physicians and Surgeons on July 27th, 2026.
Published on July 25th, 2026. Updated on July 28th, 2026.
Key takeaways
Ocaliva's only current FDA approval is for primary biliary cholangitis (PBC); every other application remains investigational or off-label.
NASH is the most clinically advanced off-label area, but the FDA declined accelerated approval in 2023 and the definitive trial is still ongoing.
Obeticholic acid carries a serious hepatotoxicity risk, especially in cirrhosis patients, making unsupervised off-label use more dangerous than with many other drugs.
Patients interested in obeticholic acid for non-PBC conditions should prioritize enrolling in a clinical trial rather than seeking an off-label prescription.
FXR agonism has broad theoretical applications across liver and metabolic conditions, but most indications beyond PBC currently lack Phase III evidence.
What Ocaliva Is Approved For
Obeticholic acid, sold under the brand name Ocaliva, received FDA approval in 2016 for adults with primary biliary cholangitis (PBC). It is indicated for patients who have had an inadequate response to ursodeoxycholic acid, or as monotherapy when that drug cannot be tolerated.
The drug works as an FXR (farnesoid X receptor) agonist. FXR is a nuclear receptor found in the liver, intestines, and kidneys that regulates bile acid production, liver inflammation, and fat metabolism. By activating FXR, obeticholic acid reduces bile acid synthesis and suppresses the inflammatory signals that drive cholestatic liver damage.
An important safety note: the FDA added a boxed warning in 2018 after reports of serious liver injury linked to incorrect dosing, particularly in patients with moderate to severe cirrhosis. This warning shapes every conversation about using the drug beyond its approved indication.
The NASH Connection: The Most Studied Off-Label Application
Nonalcoholic steatohepatitis, commonly called NASH, is one of the fastest-growing causes of chronic liver disease worldwide. It currently has no approved cure, making obeticholic acid one of the most closely watched investigational candidates.
The landmark REGENERATE trial tested obeticholic acid 25 mg against placebo in patients with NASH and liver fibrosis. At the 18-month interim analysis, patients receiving the drug showed meaningful improvements in fibrosis stage compared to the placebo group. These results were encouraging enough to support a bid for accelerated FDA approval.
However, in 2023 the FDA issued a Complete Response Letter, declining to grant accelerated approval due to uncertainty about the overall benefit-risk profile. The full REGENERATE trial is still ongoing, collecting data on harder clinical endpoints such as liver-related mortality and disease progression. Until those results are available, NASH remains an off-label and investigational use.
Investigations in Primary Sclerosing Cholangitis
Primary sclerosing cholangitis (PSC) is another bile duct disease with no approved disease-modifying therapy, which makes FXR agonism a logical investigational target. PSC shares key pathways with PBC, including disrupted bile acid homeostasis and chronic liver inflammation.
Early-phase clinical trials in PSC patients treated with obeticholic acid did show improvements in liver enzyme levels, a common biochemical marker of liver stress. However, improvements in liver enzymes do not always translate into clinical benefit, and trial results for PSC have been inconsistent.
As of 2025, no large Phase III randomized trial has established obeticholic acid as a standard of care for PSC. Patients with PSC who are interested in this option should ask their hepatologist about active trials rather than expecting routine off-label prescribing.
Other Investigational Areas Under Study
Beyond NASH and PSC, researchers have explored obeticholic acid across several other conditions where FXR biology plays a possible role.
Condition |
Approval Status |
Strength of Current Evidence |
|---|---|---|
Primary biliary cholangitis (PBC) |
FDA approved (2016) |
Strong, Phase III data |
NASH with fibrosis |
Not approved, investigational |
Moderate, Phase III ongoing |
Primary sclerosing cholangitis |
Not approved, investigational |
Weak to moderate, early-phase trials only |
Portal hypertension |
Not approved, investigational |
Weak, preclinical and early human data |
Type 2 diabetes / insulin resistance |
Not approved, research slowed |
Weak, early studies only |
Bile acid malabsorption |
Not approved, theoretical |
Very limited clinical data |
Portal hypertension has attracted some preclinical and early human research interest. FXR activation may reduce hepatic vascular resistance, potentially offering a new way to manage elevated pressure in the portal vein system. The data remain early and have not advanced to larger trials.
In the area of type 2 diabetes and insulin resistance, early studies suggested that FXR activation could improve glucose metabolism and insulin sensitivity. However, this line of investigation has slowed considerably as the primary focus shifted to NASH and fibrosis-related endpoints.
Why Off-Label Prescribing Carries Unique Risks With This Drug
Many medications are prescribed off label routinely and safely. Obeticholic acid is a case where the risks of unsupervised off-label use are meaningfully higher than average.
The boxed warning about hepatotoxicity is not a theoretical concern. Patients with cirrhosis who receive doses intended for non-cirrhotic patients can experience rapid liver decompensation. Outside of the FDA-approved PBC indication, there is no established dosing protocol. A clinician prescribing off label must extrapolate from PBC guidance and adjust based on liver function, which requires specialist-level expertise in hepatology.
Insurance coverage for off-label use is rarely available, and the out-of-pocket cost of obeticholic acid is substantial. Patients who cannot access the medication through legitimate channels and turn to compounded or unverified sources face additional safety risks from variable drug quality.
What Patients Should Know Before Exploring Off-Label Options
If you or a family member has a liver condition and you have read about obeticholic acid, there are important distinctions to understand before any conversation with a specialist.
Investigational use within a clinical trial is very different from a physician-initiated off-label prescription in routine practice. Clinical trials provide structured monitoring, standardized dosing, safety oversight, and often cover the cost of the medication. They also contribute data that may eventually help other patients. Off-label prescribing outside a trial lacks all of these safeguards.
Before asking a hepatologist about obeticholic acid, it helps to know your current fibrosis stage, your Child-Pugh or MELD score if applicable, and whether you have already tried approved therapies relevant to your diagnosis. These factors determine whether you might be a reasonable candidate and whether any trial protocols match your profile.
ClinicalTrials.gov allows anyone to search active studies by drug name or condition. Filtering for "obeticholic acid" alongside your diagnosis can surface trials that may be recruiting. Doctronic offers free AI consultations available 24/7, giving patients a way to prepare informed, specific questions before a hepatology appointment. With more than 22 million AI consultations completed and 99.2% treatment plan alignment with board-certified physicians, Doctronic can help you walk into that specialist visit ready to have a productive conversation about your options.
Frequently Asked Questions
No. As of 2025, obeticholic acid is not FDA-approved for NASH. The FDA issued a Complete Response Letter in 2023 declining accelerated approval, citing benefit-risk uncertainty. The REGENERATE trial is continuing to gather long-term outcomes data, but NASH remains an investigational use only.
A physician may technically prescribe it off label for PSC, but early-phase trials have shown only inconsistent clinical benefits. No large Phase III trial has established it as a standard treatment for PSC. Patients should discuss this option with a hepatologist and consider clinical trial enrollment instead.
Off-label use carries significant risks, including serious liver injury from incorrect dosing, particularly in patients with cirrhosis. There is no standardized dosing protocol outside of PBC guidance. Insurance rarely covers off-label use, and obtaining the drug through unverified sources raises additional safety concerns.
The REGENERATE trial found that obeticholic acid 25 mg improved liver fibrosis scores in NASH patients compared to placebo at 18 months. However, the FDA considered the benefit-risk profile uncertain and declined accelerated approval. The trial is ongoing to assess definitive clinical outcomes such as disease progression.
Obeticholic acid is an FXR (farnesoid X receptor) agonist, meaning it targets a nuclear receptor that regulates bile acid synthesis, liver inflammation, and fat metabolism. Most other liver disease medications work through different pathways. This unique mechanism is why it is being studied across multiple liver and metabolic conditions.
The Bottom Line
Obeticholic acid shows genuine scientific promise across several liver conditions, including NASH, PSC, and portal hypertension. However, PBC remains the only condition with regulatory backing. The drug's serious hepatotoxicity risk means off-label use requires close specialist supervision, careful dosing, and a clear understanding of the evidence gaps. Patients curious about obeticholic acid for non-PBC conditions should speak with a hepatologist and explore active clinical trials before pursuing an off-label prescription. Doctronic, the first AI legally authorized to practice medicine in the U.S., offers free 24/7 consultations with 99.2% treatment plan alignment with board-certified physicians, helping you prepare the right questions before your specialist visit. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
References
Related articles
Get personalized health advice
Chat Now